Fagron stock closed at €23.20 on Friday, rounding off a month where the share price drifted about 3% lower despite a fresh set of half year numbers. On a short view the market looks lukewarm. On a longer view the headline is different. Earnings per share over the trailing twelve months sit at €1.25 and the P/E multiple of 18.5x still sits below healthcare peers.

The key tension this season is not the income statement. It is the balance sheet. High debt remains the central issue that long term holders and new investors now have to price into the story.

Is Fagron trading at a genuine discount, or is the lower P/E a warning sign the market sees something you do not? See how the current share price compares with intrinsic value in our valuation analysis for Fagron

H1 2026 Earnings Summary

• Revenue (H1 2026 vs. H1 2025): €476.13 million vs. €442.62 million (higher year on year)
• Net Income (Excl. Extra Items, H1 2026 vs. H1 2025): €45.56 million vs. €40.13 million (higher year on year)
• Basic EPS (H1 2026 vs. H1 2025): €0.62 vs. €0.55 (higher year on year)
• Net Profit Margin (Trailing 12 Months vs. Prior Year): 8.9% vs. 9.3% (slight margin compression)

Prefer clean, visual charts instead of picking through raw financial tables and debt figures? See Fagron’s full balance sheet and debt profile set out in an easy to read visual dashboard in our company report for Fagron.

Fagron bull case hinges on compounding scale proof

Bulls argue that Fagron can turn its global compounding footprint and acquisition pipeline into steadily higher earnings while keeping integration under control. H1 2026 numbers give some support. Revenue of €476.13 million and basic EPS of €0.62 are both higher year on year, which indicates that portfolio expansion, including Amber in Singapore and Malaysia and five deals in H1, is not diluting earnings at group level. Net profit margin on a trailing basis is 8.9%, only slightly lower than 9.3%. Margin pressure from newer, lower margin units is present but contained for now. Management reiterating full year 2026 guidance and pushing ahead with facility enlargements, automation and a reinforced North America leadership team shows the growth plan is intact, even if not yet driving clear margin expansion.

Debt and margin pressure keep Fagron bear case alive

Bears focus on Fagron’s high debt and the risk that aggressive expansion, GLP 1 exposure and input costs eventually erode returns. The balance sheet remains the central concern in this earnings season and shareholders renewed capital authorisations for five years, which keeps the door open for more M&A rather than forced deleveraging. Trailing net margin slipped from 9.3% to 8.9%, so profitability is moving in the opposite direction of the margin expansion story. The stock is down about 3% over both 30 and 90 days, which signals investors are not rewarding the current acquisition pace or reiterated guidance. Integration is said to be progressing as planned. However, there is still no clear evidence in the margins that procurement savings and automation are offsetting mix effects from acquired, less profitable businesses.

After Fagron’s renewed capital authorisations and ongoing acquisition push, high leverage may be only the visible issue. Review our structured risk analysis for Fagron which shows 1 important warning sign

Stay Ahead With Simply Wall St

If the mix of higher revenue, slightly softer margins and a lower P/E for Fagron has your attention, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value and watch how the debt story evolves over time. Once you are invested, use the Portfolio Command Center to cut through market noise and focus on the key updates that matter for your holdings. For a broader view, tap into the Community to see how other investors are thinking about similar balance sheet and earnings trade offs. By spotting potential catalysts and risks early, you give yourself a better chance of staying a step ahead of the market.

Seeking Alternatives Beyond Fagron Stock?

Fresh ideas can move fast. Some stocks start to break out while others lose momentum and get caught dropping before most investors notice. Scan these under the radar for now picks and act now.

• Spot potential breakout stories early and sift through 524 high quality undiscovered gems that still fly under mainstream radars while the entry window is wide open.
• Balance growth and resilience as you review the curated list of solid balance sheet and fundamentals stocks (414 results) to see which businesses pair sturdy finances with room for future momentum.
• Zero in on quality income ideas and assess the 432 dividend fortresses that currently offer high yields while that combination of payout and stability still holds.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.